Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

8.0K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

15.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "On the Distinction Between Prognostic and Predictive Inference in Multicancer Early Detection" and "Interpretation of Survival Outcomes in Multicancer Early Detection Testing Requires Caution".

JCO precision oncology·2026
Same author

Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergence.

EBioMedicine·2026
Same author

Plasma signals of lung tumor promotion for molecular cancer prevention.

Cell·2026
Same author

Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.

Nature machine intelligence·2026
Same author

Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer.

Cell·2026
Same author

Subclonal immune evasion in non-small cell lung cancer.

Cancer cell·2026
Same journal

A viral ORFeome library for systems-level genetic dissection of host-pathogen interactions.

Cell·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K

Cancer Evolution Constrained by the Immune Microenvironment.

Nicholas McGranahan1, Charles Swanton2

  • 1Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK.

Cell
|August 26, 2017
PubMed
Summary
This summary is machine-generated.

Tumorigenesis is an evolutionary process driven by cancer cell competition and immune interactions. This study analyzes a patient with ovarian cancer, revealing complex tumor evolution dynamics.

More Related Videos

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.6K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Related Experiment Videos

Last Updated: Feb 24, 2026

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.1K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.6K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K

Area of Science:

  • Oncology
  • Evolutionary Biology
  • Immunology

Background:

  • Tumorigenesis is a Darwinian evolutionary process.
  • Cancer cells and the immune microenvironment dynamically interact.
  • Understanding these interactions is crucial for cancer treatment.

Purpose of the Study:

  • To investigate the evolutionary dynamics of tumor development.
  • To analyze the interplay between cancer subclones and the immune microenvironment.
  • To provide insights into advanced serous ovarian carcinoma.

Main Methods:

  • Deep analysis of a single patient's tumor.
  • Characterization of cancer subclones.
  • Assessment of the immune microenvironment.

Main Results:

  • Detailed evolutionary trajectory of tumor development identified.
  • Specific interactions between cancer subclones and immune cells elucidated.
  • Complex clonal architecture and immune evasion strategies revealed.

Conclusions:

  • Tumor development is a complex evolutionary process.
  • Immune microenvironment plays a critical role in tumor evolution.
  • Further research into patient-specific tumor evolution is warranted.